METHODS	Following a 2 - to 4-week , single-blind , placebo run-in period , patients were randomly assigned to receive imidapril at doses of up to 20 mg/d , or candesartan at doses up to 16 mg/d , once daily in a double-blind , parallel-group design with a 12-week active-treatment period .\